Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC).

Trial Profile

Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Iniparib (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms SOLTI-NEOPARP
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2017 This trial has been completed in Spain.
    • 05 Sep 2012 Planned end date changed from 1 Mar 2013 to 1 Feb 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top